GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » LT-Debt-to-Total-Asset

Divi's Laboratories (NSE:DIVISLAB) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Divi's Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Divi's Laboratories's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).


Divi's Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Divi's Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories LT-Debt-to-Total-Asset Chart

Divi's Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Divi's Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Divi's Laboratories LT-Debt-to-Total-Asset Calculation

Divi's Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )/Total Assets (A: Mar. 2024 )
=20/154700
=0.00

Divi's Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories  (NSE:DIVISLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Divi's Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories Business Description

Traded in Other Exchanges
Address
Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients with a predominance in exports. It also through its custom synthesis, supports pharma companies for their patented products business from gram scale requirements for clinical trials to launch as well as late life cycle management. Geographically, the company derives a majority of its revenue through exports to countries like the United States of America, Switzerland, and other countries.

Divi's Laboratories Headlines

No Headlines